author-photo

David Laidley

University of Western Ontario

6

Papers

2

Citations

Citation Trend

Filter By

Papers (5) Sort By

Journal Conference Others

Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS).

2021 Journal of Cancer Research and Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Quantitative 68Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with 177Lu-DOTATATE.

2021 The Journal of Nuclear Medicine
Show All
- Source
- Cite
- Save
Citations (1)
Toxicity and Tolerability of 177Lu-DOTA-TATE PRRT with a Modified Administered Activity Protocol in NETs of Variable Origin – A Phase 2 Registry Study

2021 Current Radiopharmaceuticals
Show All
- Source
- Cite
- Save
Citations (0)
Does Tumor Response Correlate With Quality of Life Changes Following LU177 DOTATATE Therapy for Neuroendocrine Tumors? Observations From a Multicenter Prospective Study (NCT02743741).

2021 International Journal of Radiation Oncology Biology Physics
Show All
- Source
- Cite
- Save
Citations (0)
Microscopic Positive Tumor Margin Increases Risk for Disease Persistence but Not Recurrence in Patients with Stage T1-T2 Differentiated Thyroid Cancer

2020 Journal of Thyroid Research
Show All
- Source
- Cite
- Save
Citations (1)